Rigel Pharmaceuticals Inc (RIGL): Total Assets
$513.59M
As of 2025-12-31
$521.07M
As of 2026-06-30
+56.4%
3-year compound annual growth
+36.0%
5-year compound annual growth
+14.6%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $513.59M | +213.2% | 2026-03-03, Balance as of period end |
| 2024-12-31 | $163.98M | +39.9% | 2026-03-03, Balance as of period end |
| 2023-12-31 | $117.22M | -12.7% | 2025-03-04, Balance as of period end |
| 2022-12-31 | $134.28M | -19.8% | 2024-03-05, Balance as of period end |
| 2021-12-31 | $167.33M | +51.6% | 2023-03-07, Balance as of period end |
| 2020-12-31 | $110.38M | -25.2% | 2022-03-01, Balance as of period end |
| 2019-12-31 | $147.57M | +6.1% | 2021-03-02, Balance as of period end |
| 2018-12-31 | $139.11M | +16.8% | 2020-02-27, Balance as of period end |
| 2017-12-31 | $119.11M | +52.4% | 2019-02-28, Balance as of period end |
| 2016-12-31 | $78.13M | -40.7% | 2018-03-06, Balance as of period end |
| 2015-12-31 | $131.75M | -14.5% | 2017-03-07, Balance as of period end |
| 2014-12-31 | $154.13M | -31.8% | 2016-03-08, Balance as of period end |
| 2013-12-31 | $226.06M | -27.1% | 2015-03-03, Balance as of period end |
| 2012-12-31 | $310.04M | +20.6% | 2014-03-04, Balance as of period end |
| 2011-12-31 | $257.11M | +37.7% | 2013-03-05, Balance as of period end |
| 2010-12-31 | $186.69M | n/a | 2012-03-06, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Rigel Pharmaceuticals Inc (RIGL) | 2025-12-31 | $513.59M | +213.2% |
| Rapport Therapeutics, Inc. (RAPP) | 2025-12-31 | $512.43M | +62.7% |
| Ardelyx, Inc. (ARDX) | 2025-12-31 | $501.60M | +15.1% |
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | $529.71M | -26.9% |
| Dianthus Therapeutics, Inc. (DNTH) | 2025-12-31 | $530.92M | +42.0% |
| Olema Pharmaceuticals, Inc. (OLMA) | 2025-12-31 | $533.43M | +18.3% |
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | $488.95M | -25.5% |
| Oruka Therapeutics, Inc. (ORKA) | 2025-12-31 | $488.62M | +23.4% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $480.20M | +22.4% |
Compare RIGL, RAPP, ARDX, SNDX side by side · Screen every company in Pharmaceutical Preparations ↗